TABLE 1.
Baseline patient characteristics.
| 15 mg dose (n = 19) | 30 mg dose (n = 49) | p value | |
|---|---|---|---|
| Age (years) | 87.5 ± 4.1 | 78.5 ± 6.9 | <0.001 |
| Male gender, n (%) | 11 (57.9) | 24 (49.0) | |
| Body weight (kg) | 49.4 ± 8.2 | 52.0 ± 8.9 | 0.31 |
| Paroxysmal atrial fibrillation, n (%) | 8 (36.8) | 22 (44.9) | |
| Serum creatinine (mg/dL) | 1.28 ± 0.39 | 1.05 ± 0.48 | 0.019 |
| Mean creatinine clearance (mL/min) | 28.6 ± 9.4 | 44.7 ± 16.7 | <0.001 |
| Mean CHADS2 score, n (%) | 3.6 ± 1.0 | 2.2 ± 1.1 | <0.001 |
| 0 | 0 | 2 (4.1) | |
| 1 | 1 (5.3) | 10 (20.4) | |
| 2 | 0 | 21 (42.9) | |
| ≧3 | 18 (94.7) | 16 (32.7) | |
| Congestive heart failure, n (%) | 19 (100) | 23 (46.9) | <0.001 |
| Hypertension, n (%) | 16 (84.2) | 29 (59.2) | 0.065 |
| Age ≧75 years, n (%) | 19 (100) | 36 (73.5) | 0.013 |
| Diabetes mellitus, n (%) | 10 (52.6) | 10 (20.4) | 0.009 |
| Baseline stroke/transient ischemic attack/systemic embolism, n (%) | 0 | 5 (10.2) | 0.15 |
| Previous anticoagulants, n (%) | |||
| None | 4 (21.1) | 24 (50.0) | |
| Warfarin | 1 (5.3) | 20 (40.8) | |
| Dabigatran | 1 (5.3) | 2 (4.1) | |
| Rivaroxaban | 3 (15.8) | 2 (4.1) | |
| Apixaban | 1 (5.3) | 1 (2.0) | |
| Edoxaban (30 mg OD) | 9 (47.4) | — | — |
| Peak AXA (IU/mL) | 0.74 ± 0.40 | 1.25 ± 0.48 | <0.001 |
| Trough AXA (IU/mL) | 0.19 ± 0.12 | 0.12 ± 0.11 | 0.080 |
| 15 mg dose (n = 16) | 30 mg dose (n = 27) | p value | |
|---|---|---|---|
| Peak PT (s) | 14.1 ± 1.8 | 16.2 ± 3.9 | 0.06 |
| Trough PT (s) | 11.9 ± 0.7 | 11.9 ± 1.6 | 0.93 |
Note: The PT values were evaluated in the part of the patients (in the 15 mg group, 16 of 19 patients, and in the 30 mg group, 27 of 49 patients) by the discretion of the attending physician.